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Abstract Mitoxantrone (MTX) is a chemotherapeutic
agent, which presents late irreversible cardiotoxicity. This
work aims to highlight the mechanisms involved in the
MTX-induced cardiotoxicity, namely the effects toward
mitochondria using in vivo and in vitro studies. Male
Wistar rats were treated with 3 cycles of 2.5 mg/kg MTX
at day 0, 10, and 20. One treated group was euthanized on
day 22 (MTX22) to evaluate the early MTX cardiac toxic
effects, while the other was euthanized on day 48
(MTX48), to allow the evaluation of MTX late cardiac
effects. Cardiac mitochondria isolated from 4 adult
untreated rats were also used to evaluate in vitro the MTX
(10 nM, 100 nM, and 1 lM) direct effects upon mito-
chondria functionality. Two rats of MTX48 died on day 35,
and MTX treatment caused a reduction in relative body
weight gain in both treated groups with no significant
changes in water and food intake. Decreased levels of
plasma total creatine kinase and CK-MB were detected in
the MTX22 group, and increased plasma levels of lactate
were seen in MTX48. Increased cardiac relative mass and
microscopic changes were evident in both treated groups.
Considering mitochondrial effects, for the first time, it was
evidenced that MTX induced an increase in the complex IV
and complex V activities in MTX22 group, while a
decrease in the complex V activity was accompanied by the
reduction in ATP content in the MTX48 rats. No alterations
in mitochondria transmembrane potential were found in
isolated mitochondria from MTX48 rats or in isolated
mitochondria directly incubated with MTX. This study
highlights the relevance of the cumulative MTX-induced
in vivo mitochondriopathy to the MTX cardiotoxicity.
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Abbreviations
ATP Adenosine 50-triphosphate
AST Aspartate aminotransferase
BN-PAGE Blue native polyacrylamide gel
electrophoresis
CK Creatine kinase
DAB Diaminobenzidine
DTNB 5,5-Dithio-bis(2-nitrobenzoic acid)
GSH Reduced glutathione
GSHt Total glutathione
GSSG Oxidized glutathione
HClO4 Perchloric acid
LDH Lactate dehydrogenase
MTX Mitoxantrone
b-NADPH Reduced b-nicotinamidephosphate adenine
dinucleotide
TPP? Tetraphenylphosphonium
Introduction
Mitoxantrone (MTX) is an antitumor agent used in the
treatment of breast and prostate cancer, acute leukemia,
lymphoma, and in the treatment of multiple sclerosis due to
its immunosuppressive properties [1, 2]. However, the
cumulative cardiotoxic profile of MTX is well known, and it
can affect up to 18 % of treated patients [1]. The MTX-
induced cardiotoxicity is irreversible, dose-dependent, and it
may occur years after treatment [3]. Clinically, MTX car-
diotoxicity is mainly characterized by a reduction in left
ventricular stroke volume and congestive heart failure [1, 3].
The risk of MTX-induced cardiac side effects increases
greatly with cumulative dose up to 140 mg/m2 [2, 3].
Human mean maximum MTX plasma concentrations are
about 1.5 and 12 lM 30 min after 15 or 90 mg/m2 intra-
venous infusion, respectively [4]. The accumulation of
MTX in the heart tissue is well documented [5, 6], with
described concentrations around 716 ng/g wet tissue
35 days after MTX single dose of 12 mg/m2 [6]. Further-
more, we highlighted that at least one biotransformation
product of MTX, the naphthoquinoxaline metabolite
(described as toxic), also accumulates in the rat heart,
evidencing a prolonged exposure of the cardiac cells to
MTX and this bioactive product [7].
Recently, we showed that therapeutic concentrations of
MTX (100 nM and 1 lM) caused an important energetic
imbalance evidenced by decreased ATP levels, hyperpo-
larization of the mitochondrial membrane potential, and a
rise in the intracellular calcium levels after 24, 48, and 96 h
of MTX incubation in a cardiomyoblast cell model (H9c2
cells) [8]. Additionally, MTX caused late inhibition of
ATP-synthase expression and activity with concomitant
increase in the reactive species generation after 96 h
incubation with both previously referred concentrations
[8]. In other studies, energetic imbalance was also observed
in cultured neonatal rat heart cells after MTX incubation
[9], and mitochondrial swelling was described in female
BALB/c mice heart after MTX treatment [10]. Further-
more, uncoupling of oxidative phosphorylation was
described in cardiac mitochondria isolated from rats treated
with MTX [11]. Even so, studies to elucidate the mecha-
nisms involved in the cardiotoxicity of MTX in vivo are
scarce, especially with focus on mitochondrial functional-
ity. Thus, the present work aims to contribute to the better
understanding the in vivo MTX-induced cumulative car-
diotoxicity using male adult Wistar rats subjected to 3
cycles of MTX treatment. MTX total cumulative dose was
7.5 mg/kg, which corresponds to 48 mg/m2 by the allo-
metric relationship, and therefore a clinical therapeutic
dose. Early and late toxic effects (2 vs. 28 days after
reaching the MTX total cumulative dose) were evaluated in
order to assess the maladaptive responses involved in the
MTX-induced cardiotoxicity. Furthermore, a complemen-
tary in vitro study, using rat-isolated cardiac mitochondria,
was performed to understand the direct effects of MTX in
the cardiac mitochondrial function.
Materials and Methods
Chemicals
All chemicals were of analytical grade. MTX hydrochloride,
reduced glutathione (GSH), oxidized glutathione (GSSG),
glutathione reductase (GR, EC 1.6.4.2), 2-vinylpyridine,
reduced b-nicotinamide phosphate adenine dinucleotide
(b-NADPH), adenosine 50-triphosphate (ATP), cytochrome
c, defatted bovine serum albumin, subtilopeptidase A type
VIII, 5,5-dithio-bis(2-nitrobenzoic acid) (DTNB), luciferin,
luciferase, subtilisin A protease, diaminobenzidine (DAB),
glutaraldehyde, formaldehyde, and osmium tetroxide were
purchased from Sigma-Aldrich (St. Louis, MO). HMW-
native marker was purchased from GE Healthcare, Buck-
inghamshire, UK. Perchloric acid (HClO4) and propylene
oxide were obtained from Merck (Darmstadt, Germany).
The reagents for the creatine kinase (CK), CK-MB, and
lactate analysis were purchased from PZ Cormay S.A.
Animals
For the in vivo study, 15 adult male Wistar rats (Charles
River Laboratories, Barcelona, Spain) weighing 240–300 g
were used. Four additional male Wistar rats, weighting
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200–250 g, were utilized for the in vitro study. The animals
were housed in cages, with a temperature and humidity
controlled environment. Food and water were provided
ad libitum, and animals were subjected to a 12 h light–dark
cycle. Animal experiments were approved by the Ethical
Committee of Faculty of Pharmacy of the University of
Porto (protocol number 09/04/2013). Housing and experi-
mental treatment of the animals were in accordance with
the Guide for the Care and Use of Laboratory Animals
from the Institute for Laboratory Research. The experi-
ments complied with current Portuguese laws.
Dose Regimen
For 1 week prior to the in vivo experiment, animals were
acclimatized in cages. Animals were distributed into 3
groups (5 animals per group): control, MTX22, and MTX48;
however, in order to allow individual measurements of food/
water consumption, rats were distributed as 1 animal per
cage. Animals were treated with 3 cycles by intraperitoneal
route (5 ml/kg), of saline solution (0.9 % NaCl) (control) or
MTX 2.5 mg/kg (MTX22 and MTX48) on day 0, 10, and 20,
the MTX-treated groups reaching a total cumulative dose of
7.5 mg/kg on day 20. The dose was calculated taking into
account previously pilot studies and the body surface area of
the rats in order to correlate the dose in this species consid-
ering human top limit of the commonly used doses [5]. Thus,
2.5 mg/kg corresponds to 16 mg/m2 of a rat weighing 240 g,
being similar to the dose administered in humans and about
one-tenth of the maximum dose allowed in humans (140 mg/
m2) [1]. The regimen of administration (1 cycle every
10 days) was performed aiming to simulate the human
chemotherapeutic cycles. The interval of 10 days was
defined taking into account the life cycle of the rat and the
clinical conditions observed in pilot studies.
During the experiment, daily clinical evaluations of all
animals were performed by the veterinary doctor of the
team. The parameters evaluated were as follows: piloe-
rection, dehydration, hemorrhage and diarrhea, motor
function (tone and movement coordination), breathing (rate
and depth, gasping), mucosal color (pale, cyanotic), and
clinical signals of abdominal pain. The individual weight
and consumption of food and water were also evaluated
daily until day 30.
The MTX22 group was euthanized on day 22, in order
to assess the MTX-induced cumulative damage 2 days
after the last cycle of treatment. MTX48 group was
euthanized on day 48, i.e., 28 days after the last cycle of
treatment, in order to evaluate the late cumulative
responses. Animals were anesthetized with xylazine/keta-
mine (10–100 mg/kg), and blood was collected through
cardiac puncture. All the procedures were equally per-
formed for control and treated rats.
Plasma Biochemical Analysis
Blood was collected into heparinized tubes. Plasma levels
of aspartate aminotransferase (AST), CK, CK-MB, and
lactate were evaluated in duplicate on an AutoAnalyzer
(PRESTIGE 24i, PZ Cormay S.A.) using the respective
kits and following the manufacturer instructions.
Tissue Preparation for Light and Transmission Electron
Microscopy
For light microscopy, heart (right and left ventricle) was
sliced in 2–4 mm3 pieces, approximately, and fixed in 4 %
formaldehyde (10–20 h, 4 C), which were further dehy-
drated with graded ethanol (Panreac, Barcelona, Spain)
concentrations and mounted in paraffin (MERK, Darms-
tadt, Germany) following routine standard procedures.
Semi-thin sections (5 lm) were cut in a microtome (Leica
Microsystems, Model RM2125) and mounted on silane-
coated slides (Sigma, S4651-72EA). After dewaxed in
xylene and hydrated through graded alcohol concentra-
tions, tissue sections were stained with haematoxylin–eosin
(Atom Scientific Ltd, England) and analyzed under a light
microscope coupled to a digital camera (Axio Imager A1,
Carl Zeiss, Oberkochen, Germany).
For transmission electron microscopy, 1 mm3 right and
left ventricle pieces were fixed in 2 % glutaraldehyde (2 h,
4 C), post-fixed with 2 % osmium tetroxide, dehydrated in
graded ethanol and later embedded in Epon (TAAB 812
Resin, Kit Cat. No. T024), using routine standard proce-
dures. Ultrathin (100 nm) sections obtained in an ultrami-
crotome (Reichert Ultracut) were mounted in copper grids
(300 Mesh, from TAAB Laboratories Equipment Ltd,
England) and further contrasted with uranyl acetate and
lead citrate for transmission electron microscopy analysis
(Zeiss EM 10A) at an accelerating voltage of 60 kV.
Isolation of Cardiac Mitochondria for the Evaluation
of Complexes IV and V Activities and Cardiac
Mitochondrial Content
Cardiac mitochondria from control and MTX-treated rats
were isolated for the evaluation of in-gel activity of complexes
IV and V and cardiac mitochondrial content. Hearts were
minced with scissors in homogenization buffer [250 mM
sucrose, 10 mM HEPES, 0.5 mM EGTA (pH 7.4)], supple-
mented with subtilpeptidase A type VIII (1 mg/g tissue).
Following 10 min of incubation on ice, albumin fat-free was
added to a final concentration of 10 mg/mL. The tissue was
subsequently rinsed three times with buffer, homogenized
with a tightly fitted Potter–Elvehjen homogenizer and Teflon
pestle, and centrifuged (14,500g, 10 min, 4 C). The resulting
pellet was resuspended in homogenization buffer free of
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enzyme, homogenized, and centrifuged (750g, 10 min, 4 C).
Mitochondria-enriched pellet was obtained by centrifuging
the resulting supernatant (12,500g, 20 min, 4 C), washed
twice, and then aliquoted for subsequent analysis [12]. Protein
content was determined with RC DC Protein Assay kit (Bio-
Rad, Hercules, CA, USA) using bovine serum albumin as
standard.
Blue Native (BN)-PAGE Separation of Mitochondria
Membrane Complexes
The BN-PAGE separation of mitochondrial membrane
complexes was performed as already described [12] using 4
animals per group. Mitochondria (200 lg of protein) were
pelleted by centrifugation (20,000g, 10 min, 4 C) and then
resuspended in solubilization buffer (50 mM NaCl, 50 mM
imidazole, 2 mM 6-aminohexanoic acid, 1 mM EDTA pH
7.0) with 1 % (w/v) digitonin. After 10 min on ice, insol-
uble material was removed by centrifugation (20,000g,
20 min, 4 C). Soluble components were combined with
0.5 % (w/v) Coomassie Blue G250, 50 mM e-amino n-
caproic acid, and 4 % (w/v) glycerol and separated on a
4–13 % gradient acrylamide gradient gel with 3.5 %
sample gel on top. Anode buffer contained 25 mM imid-
azole pH 7.0. Cathode buffer (50 mM tricine and 7.5 mM
imidazole pH 7.0) containing 0.02 % (w/v) Coomassie
Blue G250 was used during 1 h at 70 V, the time needed
for the dye front to reach approximately one-third of the
gel. Cathode buffer was then replaced for one containing
only 0.002 % (w/v) Coomassie Blue G250, and the native
complexes were separated at 200 V for 4 h at 4 C. A
native protein standard HMW-native marker (GE Health-
care) was used. The gels were stained with Coomassie
Colloidal for protein visualization and scanned with Gel
Doc XR System (Bio-Rad, Hercules, CA, USA). Band
detection, quantification, and matching were performed
using QuantityOne Imaging software (v4.6.3, Bio-Rad).
Mitochondrial DNA was quantified using the Qubit
dsDNA BR assay kit (Invitrogen, Carlsbad, CA, USA).
Samples were read in a Qubit 2.0 Fluorometer, and results
were expressed as the ratio between the mitochondrial
DNA concentration and the heart mass.
In-Gel Activity of Mitochondrial Complexes IV and V
The in-gel activity of complexes IV and V was determined
using the methods described elsewhere [12]. Briefly,
complex IV-specific heme stain in BN-PAGE gels was
determined using 10-lL horse-heart cytochrome c (5 mM)
and 0.5 mg DAB dissolved in 1 ml of 50 mM sodium-
phosphate, pH 7.2. The reaction was stopped by 50 % (v/v)
methanol and 10 % (v/v) acetic acid, and the gels were
then transferred to water.
ATP hydrolysis activity of complex V was analyzed by
incubating the native gels with 35 mM Tris, 270 mM
glycine buffer, pH 8.3 at 37 C, supplemented with 14 mM
MgSO4, 0.2 % (w/v), Pb(NO3)2, and 8 mM ATP. Lead
phosphate precipitation is proportional to the enzymatic
ATP hydrolysis activity. The reaction was stopped by
incubation with 50 % (v/v) methanol for 30 min, and the
gels were then transferred to water.
Gels were scanned with Gel Doc XR System (Bio-Rad,
Hercules, CA, USA). Band quantification was performed
using QuantityOne Imaging software (v4.6.3, Bio-Rad).
Determinations in the Cardiac Tissue
After the excision of hearts, they were washed in a
phosphate-saline buffer solution (pH 7.4), dried, and
weighted to assess the relative mass of the heart (calcu-
lated as a percentage of the total body weight on the day
of euthanasia). Afterward, heart tissue samples were
homogenized [1:4 (m/v)] in ice-cold phosphate buffer
solution (pH 7.4), with an Ultra-Turrax homogenizer and
centrifuged (3,000g, 10 min, 4 C). Aliquots were taken to
determine the glutathione status, ATP levels, and total
protein levels.
Total Glutathione (GSHt), GSH, and GSSG Levels
in the Cardiac Tissue
An aliquot of the supernatant referred previously was
added to an equal volume of HClO4 10 % (5 % as final
concentration). Samples were again homogenized and
centrifuged (16,000g, 10 min, 4 C), and the supernatant
was used to determinate the glutathione status [13]. The
GSHt and GSSG levels were evaluated by the DTNB–
GSSG reductase recycling assay, as previously described
[14, 15]. Briefly, for GSHt quantification, 200 lL of
supernatant was neutralized with 200 lL of 0.76 M
KHCO3 and centrifuged (16,000g, 5 min, 4 C). For
GSSG quantification, 10 lL of 2-vinylpyridine was added
to 200 lL of acid supernatant and shaken during 1 h on
ice prior to the neutralization step. In 96-well plates,
100 lL of sample, standard, or blank were added in
triplicate and mixed with 65 lL of fresh reagent solution
containing DTNB and b-NADPH. Plates were incubated
at 30 C for 15 min in a plate reader (PowerWaveX, Bio-
Tek Instruments) prior to the addition of 40-lL glutathi-
one reductase solution (10 U/mL). The final product of
this reaction is a colored substance, and its formation was
monitored for 3 min, at 415 nm, and compared with a
standard curve. GSH and GSSG standard solutions were
prepared in HClO4 5 % [15]. Results were expressed as
nmol/mg protein.
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Cardiac ATP Levels
An aliquot of supernatant obtained in ‘‘Determinations in
the Cardiac Tissue’’ section was added to an equal volume
of HClO4 10 % (5 % as final concentration). Samples were
again homogenized and centrifuged (16,000g, 10 min,
4 C), and the supernatant was used to determinate the
ATP levels as described before [8]. One hundred lL of
tissue homogenate was neutralized with 100 lL of 0.76 M
KHCO3 and centrifuged (16,000g, 10 s, 4 C). The ATP
levels were quantified by the bioluminescence test after the
reaction of 100-lL neutralized supernatant with luciferin/
luciferase solution. ATP standards were prepared in 5 %
HClO4. ATP intracellular contents were normalized to the
total protein content (nmol/mg of protein).
Cardiac Total Protein Quantification
An aliquot of the supernatant obtained in the ‘‘Determi-
nations in the Cardiac Tissue’’ section was diluted in 0.3 M
NaOH and was used to assess the total protein levels in the
cardiac tissue. The protein levels were determined, by a
procedure based in the Lowry method, spectrophotomet-
rically (750 nm), and using a microplate reader as previ-
ously described [14, 16].
Evaluation of the Mitochondrial Membrane Potential
After In Vivo and In Vitro Treatment with MTX
Cardiac mitochondria from control and MTX48 rats were
isolated for the assessment of the late cumulative effects
induced by MTX toward the mitochondrial membrane
potential. Moreover, an in vitro study with mitochondria
isolated from 4 untreated rat hearts (not treated with MTX),
which were euthanized through cervical dislocation, was
also performed in order to assess the direct MTX effects in
the mitochondrial function after incubation with MTX
(10 nM, 100 nM, and 1 lM).
Isolation of Cardiac Mitochondria
Hearts were minced with scissors in homogenization buffer
(250 mM sucrose, 1 mM EGTA, HEPES–KOH 5 mM, pH
7.4, and 0.1 % fat-free bovine serum albumin) supple-
mented with 0.5 mg/g tissue of protease. Samples were
homogenized using a Potter–Elvehjen homogenizer for
30 s. The suspension was then incubated on ice for 1 min,
and the homogenization step was repeated for more 30 s.
After centrifugation (11,000g, 10 min, 4 C), the pellet was
gently homogenized in the homogenization buffer and
centrifuged (800g, 10 min, 4 C). The obtained supernatant
was centrifuged (12,000g, 10 min, 4 C), and the mito-
chondria pellet was washed twice with homogenization
buffer without EGTA and bovine serum albumin. Protein
content was determined through the Biuret method.
Mitochondrial Transmembrane Potential Measurement
The mitochondrial membrane potential was measured
using an ion-selective electrode to measure the distribution
of the tetraphenylphosphonium (TPP?), as described
before [17]. The reference electrode used was a Ag/AgCl2,
and mitochondria (1 mg) were incubated with 1 ml respi-
ratory medium (130 mM sucrose, 50 mM KCl, 2.5 mM
KH2PO4, 5 mM HEPES, pH 7.4), supplemented with 2 lM
TPP? and 1.5 mM rotenone, with constant stirring, at
25 C. MTX (10 nM, 100 nM, or 1 lM) was added to the
incubation chamber. Mitochondria were energized by
adding 5 mM succinate [18]. The electrode was calibrated
with TPP? assuming Nerstian distribution of the ion across
the synthetic membrane. The mitochondrial membrane
potential was expressed in mV.
Statistical Analysis
Results are presented as mean ± standard deviation. The
evaluations of the rat relative body weight gain and the
consumptions of food and water were followed daily; thus,
the statistical analysis was performed using repeated
measures ANOVA followed by the Student–Newman–
Keuls post hoc test. In the other experiments, statistical
comparisons between groups were performed with one-
way ANOVA (in case of normal distribution) or Kruskal–
Wallis test (one-way ANOVA on ranks—in case of not
normal distribution). Significance was accepted at
p values \0.05.
Results
Cumulative signs of Toxicity After MTX Treatment
On the day 22 (2 days after the last MTX cycle), 2 rats
from the MTX22 group presented moderate piloerection.
On the day 25 (5 days after the last MTX cycle), 3 animals
from the group MTX48 showed moderate signals sugges-
tive of toxicity, namely slight dehydration, cyanosis, and
slight bleeding. In the following days, 1 of these animals
fully recovered, but the other 2 died on the day 35. The 2
remaining rats from MTX48 group did not show any sig-
nificant clinical alteration during all time course of the
study. As it can be seen in the Fig. 1, animals treated with
MTX started to decrease the relative body weight gain
compared to control group since the second cycle of drug
administration. These decreases were statistically signifi-
cant after the third cycle, when the animals treated with
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MTX reached a cumulative dose of 7.5 mg/kg, until the
day 30. This change is indicative of toxicity, and it was not
accompanied by significant alterations in food or water
consumptions (data not shown).
Plasma Changes Induced by MTX Treatment
As demonstrated in Table 1, plasma biochemical analysis
revealed a significant transient decrease in the CK levels in
the MTX22 group when compared to MTX48 group and
control group. Conversely, the CK-MB isoenzyme pre-
sented the same trend: a significant decrease in the MTX22
group versus control. Values similar to control levels were
found in the MTX48 group. The plasma lactate levels
significantly increased in the MTX48 group compared to
MTX22 and control groups (Table 1). No significant
changes were observed in the plasma AST levels in MTX-
treated groups compared to control animals (data not
shown).
Microscopic Changes in the Cardiac Structure After
MTX Treatment
Structural and ultrastructural analysis from control group
revealed a preserved cellular and tissue morphology (data
not shown). However, as shown in the Fig. 2, in both
MTX-treated hearts, light microscopy revealed dispersed
cellular and interstitial edema, diffusion of inflammatory
cells, and proliferation of connective tissue (A and B). In
the MTX48 group, dispersed areas of a more intense pro-
liferation of the connective tissue with abundant cellular
infiltration, probably by fibroblasts, and signs of obstruc-
tion in some small caliber arteries (A and B) were seen.
The transmission electron microscopy revealed edema of
cardiomyocytes (C, D, and E), lysosome activation in the
cardiomyocytes, proliferation of connective tissue (F and
E) and fibroblasts, and occupation of the endothelial space
by digiforme endothelial projections (C and E). In general,
mitochondria showed clearly defined cristae, however, with
abnormal orientations, but no signs of mitochondrial
swelling were observed. Giant mitochondria with aberrant
morphology (C, D, and E) were frequently interspaced with
normal morphology and dimensions ones. Abundant col-
lagen deposition in the interstitial space was frequently
observed in MTX48 (D and E). It is important to refer that
the cardiac damage shown in the histology was observed in
both right and left ventricles, suggesting that both sides
were equally affected by MTX. The sub-endocardial region
was more affected compared to the sub-pericardial since
the cellular edema and fibrosis were more pronounced in
this region.
Cardiac Alterations Induced by MTX
The cardiac relative mass (%) was evaluated as an indicator
of cardiotoxicity (Fig. 3). The animals, which were
euthanized on the day 22 (MTX22), did not show any
changes in the cardiac relative mass (0.27 ± 0.02 %)
compared to control group (0.27 ± 0.03 %). However, the
cardiac relative mass in the MTX48 group was signifi-
cantly higher (0.33 ± 0.03 %) when compared to control
or MTX22 group, evidencing a late cardiac response
(Fig. 3). These changes in the cardiac relative mass were
not accompanied by alterations in the cardiac total protein
levels (data not shown). No significant changes in the
GSHt, GSH, or GSSG cardiac levels were observed in any
of the end time points (data not shown).
Isolated cardiac mitochondria were used to evaluate the
activity of complexes IV and V of the mitochondrial
respiratory chain of the treated rats. As shown in the
Fig. 4a), the organization pattern of the five respiratory
chain complexes is in accordance with the described in the
literature for heart tissue [12]. No significant qualitative or
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Fig. 1 Relative body weight (%) gain of the animals treated with
MTX (3 cycles of 2.5 mg/kg) and control group. Results are presented
as mean ± standard deviation. Statistical analysis was performed
using repeated measures ANOVA followed by the Student–Newman–
Keuls post hoc test (*p \ 0.05 vs. control)
Table 1 Plasma biochemical parameters of the animals treated with
MTX (3 cycles of 2.5 mg/kg) and control group
Plasma
biomarker
Group
Control MTX22 MTX48
CK (U/L) 537.8 ± 195.6 326.5 ± 71.0* 441.3 ± 26.9 ns
CK/MB (U/L) 572.8 ± 125.9 390.3 ± 58.7* 595.6 ± 151.2 ns
Lactate
(mmol/L)
1.3 ± 0.4 1.6 ± 0.3 ns 2.6 ± 1.7*
Results are presented as mean ± standard deviation. Statistical ana-
lysis was performed using one-way ANOVA followed by the Stu-
dent–Newman–Keuls post hoc test (*p \ 0.05 vs. control)
ns not significant
*p \ 0.05 vs. control
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quantitative differences in the band pattern were observed
between groups in the BN-PAGE. The in-gel activity of
complex IV revealed significantly higher activity level in
the cardiac mitochondria from rats treated with MTX
(155.8 ± 33.6 % for the MTX22 group, 148.3 ± 14.4 %
for the MTX48 group vs. 100.0 ± 2.8 % for the control
group) (Fig. 4b). Considering the complex V activity, a
significant increase in MTX22 (172.6 ± 20.0 %) and a
significant decrease in MTX48 (58.1 ± 21.0 %) were
observed in comparison with the control (100.0 ± 8.3 %;
Fig. 4c). Regarding cardiac ATP levels, a significant
decrease in the MTX48 group (7.8 ± 1.5 nmol/mg) com-
pared to control (16.0 ± 2.8 nmol/mg) or MTX22
(17.6 ± 6.7 nmol/mg) groups was observed, as demon-
strated in the Fig. 5. However, no significant changes in the
ratio between mitochondrial DNA concentration and heart
mass were found (data not shown).
Fig. 2 Light (a, b) and electron micrographs (c, d, e) of heart tissue
sections representative of the common structural and ultrastructural
modifications observed in MTX-treated animals. In a (MTX48), it can
be observed an arteriole, with its lumen partially obstructed (arrow),
surrounded by an area of connective tissue (§); a general enlargement
of the interstitial space with dispersed swollen cardiomyocytes (with
increased inter-myofibril space) is also depicted. A focal area of
fibrosis (arrows) with abundant cellular infiltration is shown in
b (MTX48). At the ultrastructural level, an enlargement of inter-
myofibril space (#) and several giant and/or aberrant mitochondria
with abnormal cristae (asterisk) can be observed in c (MTX48),
d (MTX48), and e (MTX48); capillaries with their lumen occupied by
digiform structures are shown in c and e (arrow); interstitial collagen
fibers are also illustrated in d and, with a special amount, in e (§). The
figures refer to the left ventricle; however, similar cardiac changes
were found in the right ventricle
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Fig. 3 Heart relative mass (%) of the animals treated with MTX (3
cycles of 2.5 mg/kg) and control group. Results are presented as
mean ± standard deviation. Statistical analysis was performed using
one-way ANOVA followed by the Student–Newman–Keuls post hoc
test (*p \ 0.05 vs. control)
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Evaluation of the Transmembrane Potential in Cardiac-
Isolated Mitochondria
Transmembrane potential sustained by mitochondria upon
energization is essential for mitochondrial function. Given
the previously presented results found in vivo, we inves-
tigated the possible mitochondrial deleterious effect of
MTX using cardiac mitochondria isolated from MTX48
group. Altogether, no significant changes in the TPP?
assay were observed for the MTX48 mitochondria com-
pared to control group. However, mitochondria from 2
animals presented an increased lag phase, demonstrating a
difficulty to repolarize and sustain the mitochondrial
potential (data not shown).
When mitochondria from untreated rats were incubated
with 3 different MTX concentrations (10 nM, 100 nM, and
1 lM), energization phase (initial transmembrane
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Fig. 4 a BN-PAGE profile of mitochondria isolated from control,
MTX22, and MTX48 groups. An overlap of the density variation in
the lanes of the 3 groups is presented on the left. b Representative
image and graphic representation of histochemical staining of the in-
gel activity of complex IV. c Representative image and graphic
representation of histochemical staining of the in-gel activity of
complex V. Results are presented as mean ± standard deviation.
Statistical analysis was performed using Kruskal–Wallis test
(ANOVA on ranks) followed by the Student–Newman–Keuls post
hoc test (*p \ 0.05 vs. control)
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Fig. 5 Cardiac ATP levels of the animals treated with MTX (3 cycles
of 2.5 mg/kg) and control group. Results are presented as
mean ± standard deviation. Statistical analysis was performed using
Kruskal–Wallis test (ANOVA on ranks) followed by the Student–
Newman–Keuls post hoc test (*p \ 0.05 vs. control)
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potential, depolarization induced by the addition of ADP,
repolarization, or lag phase) was not affected when com-
pared to control (data not shown).
Discussion
In the present work, for the first time, the MTX-induced
cumulative cardiotoxicity was ensued after the adminis-
tration of reliable doses of MTX to rats evaluated at 2
different endpoints: 2 days after the last cycle of treat-
ment (MTX22) and 28 days after the last MTX admin-
istration (MTX48). The cardiotoxicity of MTX was
verified through the changes in the cardiac structure as
showed by the transmission electron and optic micros-
copy (Fig. 2) and by the increases in the % of relative
heart mass per body weight observed in the MTX48
group (Fig. 3). The major contribution of this study was
to show, for the first time, the different effects on
mitochondrial respiratory chain with similar MTX dose
and schedule regime of administration in vivo when
animals were euthanized at two distinct endpoints. It
became evident that mitochondrial function alterations
were more pronounced in the later time point, as seen by
the presence of aberrant mitochondria, changes of mito-
chondrial complexes IV and V activities, and depletion of
cardiac ATP levels all in MTX48 animals. On the other
hand, in MTX22 rats, increases in mitochondrial com-
plexes IV and V was observed with no significant
alteration in cardiac ATP levels when compared to con-
trol rat hearts.
The in vivo model employed in the present work seems
to be appropriate to study cumulative toxicity induced by
MTX treatment, since it reproduced human clinical
observations, such as the late development of cardiotox-
icity. This is an important point regarding the difficulties to
pharmacologically induce a heart failure condition in lab-
oratory animal models [19].
Although clinical aspects of doxorubicin and MTX are
partially the same, the underlying mechanisms seem to
differ. In fact, the MTX-induced cardiotoxicity may have
its origin in its interference with cardiac energetic metab-
olism instead of oxidative stress [8, 10, 11, 20, 21]. In the
present study, no observed significant alterations in the
cardiac glutathione levels (GSHt, GSH, and GSSG) were
found, which is in accordance with our previous in vitro
results [8]. Even so, significant changes in ATP levels were
found in MTX48 group. The sequence of events in the
establishment of a failing and energy-starved heart usually
follows a time course, first with decreases in the phos-
phocreatine levels, followed by the creatine loss, and,
ultimately, by ATP depletion [22]. Decreases in the total
CK activity and CK-MB, as observed in the MTX22 group
(Table 1), may be interpreted as a hallmark of the heart
failure development [23]. However, all signaling pathways
involved in CK alterations remain to be elucidated [23].
The development of late MTX-induced cardiotoxicity was
characterized by the energetic depletion observed in the
MTX48 group. It is well known that the loss of ATP in the
failing myocardium is a slow and progressive phenomenon,
only being detectable in the presence of a severe heart
failure [22]. Plasma lactate levels increased in the MTX48
group in comparison with MTX22 and control levels
(Table 1), and it was accompanied by depletion in the ATP
cardiac levels and increase in the cardiac relative mass,
suggesting a cardiac failure condition. Increased levels of
plasma lactate, as observed in the MTX48 group (Table 1),
are suggestive of lactic acidosis and occur in response to
tissue hypoxia, uncoupling of oxidative phosphorylation,
congestive heart failure, generalized cachexia (due to
increased anaerobic glycolysis in the skeletal muscle), or
in situations where the hepatic clearance is compromised
[23, 24]. At MTX48, apparently, an energetic shift occur-
red, and the glycolytic pathway seems to be the major
supplier of cardiac ATP, not being enough to warrant a
healthy heart. In fact, when failing, the heart assumes the
fetal pattern, switching the main energetic substrate source
from fatty acids to glucose [23]. However, as efficiency of
glucose oxidation is reduced, more lactate is generated
[23], and the energetic impairment was evidenced by the
depletion of the ATP cardiac levels in MTX48 rats (Fig. 5).
In fact, it was described that failing human hearts have
about 25–40 % less ATP than healthy hearts, and hearts in
energetic starvation fail to support an increase in the
workload [22, 25]. Indeed, the length of time that the heart
can survive with such ATP depletion still remains unclear
[22]. The energetic imbalance caused by MTX was already
demonstrated in vitro, after incubation of MTX with cul-
tured neonatal cardiomyocytes isolated from rats [9] and
with H9c2 cells [8].
The late MTX-induced mitochondrial degeneration was
also evidenced by aberrant mitochondrial morphology and
subsequent functional studies. Microscopic changes in the
cardiac mitochondrial architecture (namely cristolysis and
swelling) were observed in vitro [26] and in vivo [10, 11]
with MTX. In the present study, the mitochondrial cristae
are well defined, but in many organelles, they are abnor-
mally oriented, without signs of swelling. The mitochon-
drial morphologic changes are restricted to giant and
aberrant aspect (Fig. 2). One hypothesis that could explain
this finding is the MTX ability to intercalate into the DNA
molecule causing double and single breaks and inhibiting
DNA and RNA synthesis [27], which may compromise the
mitochondrial turnover.
The activity of mitochondrial IV and V complexes was
also evaluated in both time points. Increased levels of the
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complex IV activity were found (Fig. 4), while interest-
ingly, when considering complex V, its activity increased
in MTX22 group and decreased in the MTX48 (Fig. 4). At
MTX22, increases in the activity of the complexes IV and
V may be the result of a mitochondrial adaptation to pro-
duce more ATP in response to MTX toxic effects. Indeed,
in the MTX22 group, no significant differences in the ATP
cardiac content compared to control rats were observed
(Fig. 5), showing at this time point that the increased
activity of the mitochondrial complexes is sufficient to
maintain ATP overall levels. However, about one month
after the last MTX administration, despite the increase in
the complex IV activity, a decrease in complex V activity
was observed. In fact, MTX48 rats failed to support the
cardiac ATP demand, as observed by decreased cardiac
overall ATP levels (Fig. 5). To the best of our knowledge,
these results were evidenced for the first time in vivo and
were corroborated in vitro (using H9c2 cells) by our
research group on ATP-synthase activity using low MTX
levels [8]. Conversely, a reduction in the electron transfer
activity of state III and a concomitant uncoupling of oxi-
dative phosphorylation were already observed in cardiac
mitochondria isolated from MTX-treated female rats
(2 mg/kg, twice a week, for 4 weeks) [11]. ATP decreased
levels can be associated with an inhibited ATP synthesis
inhibition (as suggested in this work by the late decreases
in the complex V activity), but changes in the ATP levels
in the failing myocardium can also be related to the loss of
total tissue purines [25], whose levels were not evaluated in
the present work.
The mitochondrial effects herein demonstrated in vivo
were not observed by the direct incubation of MTX with
cardiac mitochondria isolated from untreated rats. The
cardiac mitochondria incubated with MTX did not show
any change in the mitochondrial functionality evaluated by
the distribution of TPP? assay. As already stated, MTX
metabolism exerts a pivotal role to the MTX-induced
toxicity [7]. Thus, the direct toxic effect mediated by MTX
may be residual and insufficient to elicit significant alter-
ations in this in vitro model without previous biotransfor-
mation. Moreover, when cardiac mitochondria were
isolated from MTX-treated rats and subjected to the TPP?
assay, remarkable heterogeneous results were seen: some
animals had fully functional mitochondria, and others
presented mitochondria with prolonged lag phase (data not
shown). Hence, these data are suggestive that the MTX
metabolism seems to be decisive to the toxicity induced by
MTX, and differences in the metabolic rate might be
behind the intersubject variability observed in the clinical
evaluations presented in this work and in human MTX
therapy.
In summary, it was demonstrated that MTX induces a
relevant cumulative mitochondriopathy evidenced by
several indicators of mitochondrial damage: MTX causes
aberrant mitochondria and interferes in vivo with the
mitochondrial functionality causing an imbalance in the
mitochondrial function that results in late ATP depletion
and, consequently, a dysfunctional heart. After depletion of
its energetic content, the cardiac performance is impaired.
Hence, this study highlights the relevance of the MTX-
induced mitochondrial toxicity to the MTX-related
cardiomyopathy.
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